1 Guidance

1 Guidance

1.1 Current evidence on limited macular translocation for wet age-related macular degeneration (AMD) shows that this procedure is efficacious in only a proportion of patients and that there is a potential for serious adverse events. Therefore the procedure should only be used with special arrangements for clinical governance, consent and audit or research.

1.2 Clinicians wishing to undertake limited macular translocation for wet AMD should take the following actions.

  • Inform the clinical governance leads in their Trusts.

  • Ensure that patients and their carers understand the uncertainty about the procedure's safety and efficacy and provide them with clear information about both this procedure and alternative treatments (see section 2.5.1). In addition, the use of NICE's information for patients ('Understanding NICE guidance') is recommended.

  • Audit and review clinical outcomes of all patients having limited macular translocation for wet AMD (see section 3.1).

  • National Institute for Health and Care Excellence (NICE)